Invesco PowerShares Leading the Intelligent ETF Revolution(r)
Welcome, Guest
Sign In  |  Register
Search
 
 
 
 
 

The PowerShares Global Biotech Portfolio (Fund) is based on the NASDAQ OMX Global Biotechnology IndexSM (Index). The Fund will normally invest at least 90% of its total assets in securities that comprise the Index and ADRs and GDRs based on the securities in the Index. The Index is designed to measure the overall performance of globally traded securities of the largest and most liquid companies involved in the biotechnology industry. The Index is rebalanced quarterly using a modified, market-cap-weighted methodology.

Go to:   Performance | Distributions | Top Holdings | Sectors
Literature:  Prospectus | Fact Sheet
Links:   Fund Holdings | Interactive Charting | Download Historical NAVs

Date   11/19/2009  
Price   23.11  
Bid/Ask Midpoint   22.89  
 
NAV   22.71  
Bid/Ask Prem/Disc   0.18  
Bid/Ask Prem/Disc   0.77%  

 As of 9/30/2009
Index History (%)1 Year3 Year5 Year10 YearFund Inceptiona
NASDAQ OMX Global Biotech Index-2.41-3.83
MSCI EAFE Index3.233.23
S&P 500 Index-6.91-6.91
Fund History (%)1 Year3 Year5 Year10 YearFund Inceptiona
NAV-2.09-3.67
After Tax Held-2.09-3.67
After Tax Sold-1.36-3.12
Market Price-1.40-4.24
aFund and underlying Index returns are based on the inception date of the Fund. Returns for the benchmark indexes are based on the closest month end to the Fund's inception date.
Monthly Standardized Report


As stated in the Fund's prospectus, the expense ratio of 0.75% is expressed as a unitary fee to cover expenses incurred in connection with managing the portfolio.


Total returns are based on the closing market price. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Performance data quoted represents past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate, and shares, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than performance data quoted. After-tax returns reflect the highest federal income tax rate but exclude state and local taxes. Fund performance reflects fee waivers, absent which, performance data quoted would have been lower. After Tax Held and After Tax Sold are based on NAV.


 As of 9/30/2009
Data beginning 9/30/2008, the month end following Fund inception
An investor cannot invest directly in an index. The results assume that no cash was added to or assets withdrawn from the Index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

  Bid/Ask MidPoint Above NAV Bid/Ask Midpoint Below NAV
Quarter Days 50-99
Basis Points		 100-199
Basis Points		 H200
Basis Points		 50-99
Basis Points		 100-199
Basis Points		 H200
Basis Points
12/31/2009 22 21 0 0 0 0 0
9/30/2009 63 20 2 10 2 0 0
6/30/2009 63 8 1 11 2 2 0
3/31/2009 61 16 2 1 0 1 1
Fund Inception: 9/18/2008

Multi-Cap Core Style Fund
Large-Cap Growth 48.54
Mid-Cap Growth 26.54
Small-Cap Growth 24.91
As of 11/19/2009


Country
United States 77.79%  
Australia 8.76%  
Switzerland 4.72%  
Spain 4.50%  
Austria 1.52%  
Netherlands 1.26%  
United Kingdom 0.54%  
France 0.48%  
Denmark 0.42%  
As of 11/19/2009


Fund Holdings subject to change  
CSL Ltd.   8.76%  
Celgene Corp.   8.57%  
Gilead Sciences Inc.   8.46%  
Amgen Inc.   7.69%  
Genzyme Corp.   7.30%  
As of 11/19/2009    
 
 
Vertex Pharmaceuticals Inc.   4.24%  
Actelion Ltd.   4.04%  
Human Genome Sciences Inc.   3.97%  
Cephalon Inc.   3.95%  
Biogen Idec Inc.   3.72%  

View All Fund Holdings




As of 11/19/2009



There are risks involved with investing in ETFs including the possible loss of money. The Fund is not actively managed and is subject to risk similar to stocks, including those related to short selling and margin maintenance. Ordinary brokerage commissions apply.

Investment in the securities of non-U.S. issuers involves risks beyond those associated with investments in U.S. securities, including, but not limited to, greater market volatility, the availability of less reliable financial information, higher transactional costs, taxation by foreign governments, decreased market liquidity, political instability, changes in currency exchange rates, interest rate fluctuation and monetary policy changes.

Investments focused in a particular industry are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments. There are additional risks associated with investing in the biotechnology industry.

Shares are subject to risks including: Small and Medium-Sized Company Risk - investing in securities of small and medium-sized companies involves greater risk than is customarily associated with investing in more established companies.

Shares are not individually redeemable and owners of the Shares may acquire those shares from the Fund and tender those shares for redemption to the Fund in Creation Units only, typically consisting of aggregations of 50,000 shares.

The MSCI EAFE® Index and the S&P 500® Index are unmanaged indexes considered representative of stocks of Europe, Australasia and the Far East; and the U.S. stock market, respectively. Except where indicated otherwise, all information is as of date noted, and Invesco PowerShares Capital Management LLC is either the source of such data or has obtained it from third-party financial reporting sources.

NASDAQ®, OMX™ and NASDAQ OMX Global Biotechnology IndexSM are trade/service marks of The NASDAQ OMX Group, Inc. (which with its affiliates is referred to as the "Corporations") and are licensed for use by Invesco PowerShares. The Product has not been passed on by the Corporations as to its legality or suitability. The Product is not issued, endorsed, sold, or promoted by the Corporations.

THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THE PRODUCT.

For more information regarding the PowerShares Global Biotech Portfolio or any of the Invesco PowerShares products, please call 800.983.0903.
As of 11/20/2009 12:00 AM EST
Last Trade $23.11
Current IIV $22.67
Change 0.00
% Change 0.00%
As of 11/19/2009
Market Close
NAV 22.71
As of 11/19/2009
SEC 30 Day Yield 0.00%
Distribution Yield N/A
12 Month Yield 0.00%
As of 11/20/2009
Previous Close $23.11
Open $0.00
Today's High $0.00
Today's Low $0.00
Today's Volume 00
52 Week High $26.00
52 Week Low $17.37
Shares Outstanding 0.2MM
Market Value $3.4MM
Fund Ticker PBTQ
CUSIP # 73936Q801
ISIN US73936Q8015
Intraday NAV PBTQ.IV
Index Ticker QGBI
Expense Ratio 0.75%
Marginable Yes
Short Selling Yes
Options No
Exchange NASDAQ
Inception Date 9/18/2008
# of Holdings
as of 11/19/2009		 44
1 year | 3 year | YTD
Interactive Charting
As of 9/30/2009
Price/Earnings Ratio¹ 47.48
Price/Book Ratio¹ 3.87
ROE² 6.61%
Avg Market Cap² 15,286MM
¹Weighted Harmonic Average
²Weighted Average
Calculation of the premium or discount of the Bid/Ask Midpoint price at the time of calculation of the NAV against such NAV.
The Intraday Indicative Value for an ETF is typically published under a seperate symbol every 15 seconds over the Consolidated Tape and calculated throughout the trading day based on the last sale prices of the securities specified for creation and redemption plus any estimated cash amounts associated with the creation unit, all on a per-ETF share basis.
A standard yield calculation developed by the Securities and Exchange Commission that allows for a common ground comparison of yield performance. It is based on the most recent 30-day period. It is calculated by dividing the net investment income (less expenses) per share over a 30-day period by the current maximum offering price.
The yield represents a single distribution from the fund and does not represent the total return of the fund. The yield is calculated by annualizing the most recent distribution and dividing by the fund NAV from the as of date. N/A will be displayed if the fund did not make a distribution in the most recent quarter.
The sum of a fund's total trailing 12-month interest and dividend payments divided by the last month's ending share price (NAV) plus any capital gains distributed over the same period.
For a description of the application of the Expense Cap and the Gross Ratio and Net Ratio please see the Fund's current prospectus.
Provides the total gross annual fund operating expenses per the Fund's current prospectus.
Provides the expected expense ratio charged to shareholders per the Fund's current prospectus and reflects the investment advisor's contractual agreement to waive a portion of its fees and/or pay Fund expenses at least until 11/20/2009.
The share price divided by earnings per share.
The price per share divided by accounting book value per share.
Net income divided by net worth.
The average market value of a company's outstanding securities, excluding current liabilities. Under $3.5 billion is generally considered small cap; $3.5 billion to $9 billion is mid cap; and over $9 billion is large cap.
A method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones.
This number indicates the number of trading days represented within the most recent quarter displayed.
New lower expenses. Click icon for more information.
©2009 Invesco PowerShares Capital Management LLC
PowerShares® is a registered trademark of Invesco PowerShares Capital Management LLC (Invesco PowerShares). Invesco PowerShares Capital Management LLC and Invesco Aim Distributors, Inc. are indirect, wholly owned subsidiaries of Invesco Ltd.
Invesco Aim Distributors, Inc. is the distributor of the PowerShares Exchange-Traded Fund Trust, the PowerShares Exchange-Traded Fund Trust II, the PowerShares India Exchange-Traded Fund Trust and the PowerShares Actively Managed Exchange-Traded Fund Trust.
Investment products offered are: Not FDIC Insured  • No Bank Guarantee  • May Lose Value
View the Legal Notice